MedTrace Logo

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

NCT01472627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2018-01-11

No results posted yet for this study

Summary

The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.

Conditions

Interventions

PROCEDURE

Blood draws

Blood draws

Sponsors & Collaborators

Principal Investigators

  • Jacalyn Rosenblatt, MD · Beth Israel Deaconess Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01472627 on ClinicalTrials.gov